A panel of experts discusses recent updates in the role of bispecific antibodies in the treatment of multiple myeloma, and the optimal strategies for monitoring and managing infections in patients receiving treatment with bispecifics.
EP. 1: Overview of Bispecific Antibodies in Multiple Myeloma TreatmentMay 10th 2023
Dr Robert Mancini summarizes the role of BCMA-targeted bispecific antibodies in multiple myeloma treatment and the side effects usually seen.
EP. 2: Infection Patterns of Bispecific Antibodies in Multiple Myeloma TreatmentMay 10th 2023
Robert Mancini, PharmD, and Kiah Purcell, AGPCNP-B, discuss other targets for bispecific antibodies in multiple myeloma treatment and the infection patterns.
EP. 3: Patient Case 1: A 69-Year-Old Male With Relapse/Refractory IgG Lambda Multiple MyelomaMay 17th 2023
Annel Urena, RN, BSN, presents the case of a 69-year-old male with relapsed refractory IgG Lambda multiple myeloma after six lines of therapy.
EP. 4: Patient Case 2: A 74-Year-Old Male With Kappa LC Multiple MyelomaMay 17th 2023
Nurse Practitioner Kiah Purcell presents a case of a 74-year-old male with kappa light chain myeloma after ten lines of therapy.
EP. 5: Patient Case 3: A 79-Year-Old Female With IgG Kappa Multiple MyelomaMay 24th 2023
Registered Nurse Annel Urena presents the case of a 79-year-old female with IgG Kappa multiple myeloma and five previous lines of therapy.
EP. 6: Educating Infusion Nurses on Infection Risks of Anti-BCMA Bispecific Antibodies in MM TreatmentMay 24th 2023
Experts discuss how they educate infusion nurses and other colleagues treating patients with multiple myeloma on the infection risks of BCMA-targeting bispecific antibodies.